1957: a quinone in the heart muscle
Frederick Crane and colleagues isolated Q10 from bovine heart mitochondria. Elucidation of its structure and the name “ubiquinone” highlighted that this redox carrier occurs in almost all cells.
AFEGA Research GroupSubstance profile 02 · Coenzyme Q10
Q10
A molecule in motion — between energy, cardiac medicine and healthy ageing.
Coenzyme Q10 is not a single, unchanging active substance. Ubiquinone and ubiquinol continually change form, connecting mitochondrial energy production with the protection of biological membranes. This profile tells how this gave rise to medical uses, personal experiences and worldwide supplementation practices.
Why Q10 fascinates
Four strands shaped today’s picture.
Biochemical discovery, cardiac medicine, orthomolecular practice and formulation innovation gave rise to one of the most enduring stories in modern supplement research.
From molecule to cardiac medicine
Karl Folkers and clinical pioneers connected low Q10 levels, the heart’s high energy requirements and early treatment experiences. Q10 became an adjunctive medical approach before it was a widely used supplement.
The “miracle nutrient”
Orthomolecular authors extended the cardiac strand to immunity, exhaustion, ageing and life extension. Emile Bliznakov’s “The Miracle Nutrient” gave this expansion a powerful popular image.
The competition between formulations
Oil-based softgels, crystal dispersions, water-dispersible systems, liposomes and, since 2007, stabilised ubiquinol made absorption itself a research topic — and the core of competing quality narratives.
From “heart nutrient” to mitochondrial stack
In integrative medicine, fertility medicine and biohacking, Q10 became associated with statins, migraine, sperm and egg quality, PQQ, NADH, carnitine and selenium. The shared guiding idea is that a fundamental redox carrier could be especially important where energy demand, oxidative turnover or ageing processes challenge the system.
The CoQ10 redox system
Not active or inactive — but a cycle.
The quinone head accepts and releases electrons and protons. This very alternation makes Q10 a mobile intermediary between energy production and membrane protection.
Oxidised form
Ubiquinone-10
accepts electrons and is chemically more stable. It is a functional partner in electron transport — not an inactive precursor.
Intermediate state
Semiquinone
carries one electron and is functionally relevant in the Q cycle. It is not a separate supplement ingredient.
Reduced form
Ubiquinol-10
donates electrons and can scavenge lipid radicals. It is more susceptible to oxidation and is converted back to ubiquinone in the body.
Both forms are biologically functional. Their significance lies in the alternation.
History of effects and research
What people associate with Q10.
Each card first gives due consideration to the proposed effect, its origins and documented experience. The optional in-depth section then presents the current overall assessment.
01
Cellular energy and mitochondrial function
The proposed effect
Coenzyme Q10 is associated with energy production in every cell. People use it seeking greater vitality, physical resilience and a good supply to particularly energy-hungry organs such as the heart, muscles and brain.
Where it comes from
This idea has an exceptionally strong biological starting point. Q10 transports electrons and protons in the mitochondrial respiratory chain, helping build the gradient from which ATP is produced. Its indispensable endogenous function gave rise to the practical idea that additional Q10 could support the cellular energy supply.
Experience and meaning
Personal reports describe more daytime energy, less tiredness and better resilience. Some people notice changes after a few weeks; others change the form, dose, timing relative to meals or duration of use until they find a practice that suits them.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 50 %
The basic biochemical function is supported by high-quality evidence, but the inference of a general benefit from additional intake is indirect. View the assessed studies →
What is the current state of research?
The current state of research
The role of endogenous CoQ10 in the respiratory chain and ATP formation is well supported scientifically. This is distinct from whether additional oral Q10 produces more ATP, noticeable energy or better performance in people without a defined deficiency. Human research reliably shows higher blood levels, but not consistent objective performance gains. Positive fatigue findings concern subjective symptom scores and are therefore assessed in a separate chapter.
02
Heart function and chronic heart failure
The proposed effect
The oldest medical Q10 tradition sees the substance as a partner of the energy-demanding heart muscle. Q10 has been used as an adjunctive approach in heart failure and cardiomyopathies — aiming to support cardiac energy, exercise tolerance and the long-term course.
Where it comes from
Early measurements of low Q10 concentrations in heart disease, clinical observations and work by researchers such as Karl Folkers, Gian Paolo Littarru, Peter H. Langsjoen and Svend Aage Mortensen shaped this tradition. Medicinal use in Japan and international research networks helped spread it.
Experience and meaning
In the clinical advocacy tradition, Q10 is described as an addition to usual treatment. Reports describe better exercise tolerance, fewer symptoms and the sense of providing the heart with a factor central to its energy work.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 65 %
Randomised long-term data with clinical endpoints exist, but rely heavily on Q-SYMBIO and older background therapy. View the assessed studies →
What is the current state of research?
The current state of research
This is the strongest general positive clinical signal. In Q-SYMBIO, 420 people with chronic heart failure received 300 mg ubiquinone daily or placebo in addition to the standard therapy of the time. After two years, the major composite cardiovascular endpoint occurred in 15 rather than 26 percent; mortality and heart-failure hospital admissions were also lower. A Cochrane review rated the mortality and hospitalisation signals as moderately certain, while stressing small studies, risks of bias and heavy dependence on Q-SYMBIO. Q10 is therefore a serious candidate for adjunctive therapy, but not a replacement for today’s guideline-based heart-failure treatment.
03
Statin therapy and muscle symptoms
The proposed effect
Q10 is one of the best-known complementary approaches to muscle symptoms during statin use. The practical idea is that when statins inhibit the shared mevalonate pathway and thereby lower Q10 levels, supplementation can help the muscles.
Where it comes from
The model links biochemistry, clinical observation and integrative medicine. Andrew Weil and other medical advocates brought the statin–Q10 connection to a broad audience. In later retellings, this often became a firm rule that everyone taking statins needed Q10 or ubiquinol.
Experience and meaning
Many users report less muscle pain, better exercise tolerance or a lighter feeling in their legs. Because statin symptoms and their causes can differ greatly between individuals, a substantial self-experimentation practice involving different forms and doses has developed.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 50 %
Several small positive RCTs, but heterogeneous symptom definitions, formulations and results. View the assessed studies →
What is the current state of research?
The current state of research
Statins can lower plasma Q10. This does not automatically imply a clinically relevant muscle deficiency, because some of the plasma reduction is explained by less LDL acting as a carrier. Intervention studies conflict: a 2025 meta-analysis found an average reduction in pain, while other syntheses found no significant benefit. Small samples, differing definitions, statins, formulations and subjective scales limit certainty. Individual improvement is possible; a routine benefit for everyone treated with statins is not currently established.
04
Tiredness, physical energy and performance
The proposed effect
The link between ATP, muscular work and subjective vitality gave rise to the idea that Q10 could reduce tiredness, aid recovery and support physical performance.
Where it comes from
Clinical fatigue studies, sports-science investigations and everyday experiences fed into a shared energy narrative. In functional medicine and biohacking, Q10 is also combined with PQQ, NADH, carnitine or magnesium in so-called mitochondrial stacks.
Experience and meaning
Users pay attention to daytime energy, climbing stairs, walks, training, recovery time and feelings of mental or physical alertness. Some prefer taking Q10 in the morning because they experience it as activating.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 55 %
Many small studies using subjective fatigue scales across very different diseases and populations. View the assessed studies →
What is the current state of research?
The current state of research
A meta-analysis of 13 randomised studies involving 1.126 participants found a small to moderate reduction in fatigue scores. Populations, measurement instruments and treatment durations varied greatly, so certainty in the average effect remains low. Objective sports and performance endpoints such as VO2, strength, time-trial performance or work economy do not improve consistently. Less subjective exhaustion and greater objective performance capacity are therefore separate claims.
05
Migraine prevention
The proposed effect
Q10 is used to prevent migraine, especially when the condition is understood as an expression of reduced mitochondrial energy reserves. In practice it is used alone or with magnesium and riboflavin.
Where it comes from
Mitochondrial models of migraine became linked with small clinical studies and observations of lower Q10 levels in certain patient groups. This gave rise to a preventive approach intended for longer-term use.
Experience and meaning
For those affected, fewer migraine days, shorter attacks and a more predictable daily life matter. Experiences are often observed over several months because a preventive effect is not assessed like an acute treatment.
Origins & experienceMigraine meta-analysis ↗
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 55 %
Small controlled studies with mostly positive frequency and duration signals, but limited precision. View the assessed studies →
What is the current state of research?
The current state of research
A meta-analysis of six studies involving 371 participants found fewer attacks and shorter migraine duration, but no consistent reduction in pain severity. The field is small, and age, dosage and accompanying treatments differ. The appropriate assessment is therefore a positive but limited signal for prevention — not for acute treatment and not for every clinical dimension.
Sources for the current assessmentSazali 2021 ↗
06
Blood pressure, endothelial function and blood vessels
The proposed effect
Q10 is associated with good vascular function, healthy circulation and balanced blood pressure. In this idea, the reduced form ubiquinol plays a special role as a protective factor for membranes and lipoproteins.
Where it comes from
Antioxidant, endothelial and vasodilatory models met small human studies on flow-mediated dilation, arterial stiffness and blood-pressure regulation. Naturopathic sources consequently incorporated Q10 into cardiovascular practice.
Experience and meaning
People monitor blood-pressure readings, exercise tolerance and their general sense of circulatory stability. Use is often understood as long-term vascular care rather than a single short-term effect.
Origins & experienceEndothelial function ↗
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 50 %
Small surrogate-endpoint and blood-pressure studies with some positive results and methodological heterogeneity. View the assessed studies →
What is the current state of research?
The current state of research
Meta-analyses of small studies report improvements in flow-mediated dilation, a surrogate marker of endothelial function. Some small systolic blood-pressure changes are found, depending on population and analysis; a stricter Cochrane review found no clinically meaningful evidence. Q10 has not been shown to prevent heart attacks or strokes or to replace blood-pressure treatment. Vascular markers, blood-pressure readings and clinical events remain separate endpoints.
07
Male and female fertility
The proposed effect
In fertility medicine, Q10 is associated with sperm protection, the energy supply to egg cells and more favourable embryonic development. Ubiquinol in particular is common in preconception protocols.
Where it comes from
Sperm motility, oxidative stress and the high energy requirements of egg maturation provided a shared biological rationale. Studies on semen parameters, oocyte counts and embryology made Q10 a frequently discussed component of preparation periods lasting several months.
Experience and meaning
Users and fertility centres align their practice with the biological time windows of gamete maturation. Reports describe divided doses, intake with meals and a lead-in period of several months.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 50 %
Several studies report semen or ovarian surrogate endpoints, often with small samples and numerous endpoints. View the assessed studies →
What is the current state of research?
The current state of research
Randomised studies and meta-analyses show positive signals for sperm motility, concentration or morphology. In diminished ovarian reserve, more retrieved oocytes and some more favourable embryology parameters were observed. The gap to the outcome most relevant to patients remains crucial: a higher live-birth rate is not established. Improved semen, egg-cell or embryo parameters must therefore not be equated with demonstrated success in achieving a birth.
08
Ageing, antioxidant protection and longevity
The proposed effect
Many people regard Q10 as a foundational substance for healthy ageing: for mitochondrial energy, protection against oxidative stress, maintenance of vitality and the longest possible healthspan. In biohacking, it is combined with PQQ, NAD precursors or selenium as a mitochondrial building block.
Where it comes from
The narrative connects age-related changes in the Q10 system with animal experiments, Emile Bliznakov’s book “The Miracle Nutrient”, antioxidant research and later combination studies such as KiSel-10. The biologically indispensable redox carrier thus became a symbol of “Life Extension” and mitochondrial self-care.
Experience and meaning
Here, people take Q10 not for a single symptom but as part of a long-term strategy. Subjective energy, confidence in one’s body and the sense of supporting a central ageing mechanism shape this practice.
Evidence base behind the proposed effect
Overall strength of this supporting evidence base:approx. 40 %
Mechanistic links to ageing and combination studies are scientifically interesting, but indirect for Q10-related longevity. View the assessed studies →
What is the current state of research?
The current state of research
Age can be associated with altered Q10 concentrations in particular tissues or blood fractions; the direction and magnitude are not uniform throughout the body. KiSel-10 found positive long-term cardiovascular signals for Q10 plus selenium in older Swedes with low selenium status. The contribution of Q10 alone cannot be determined from this. For Q10 alone, there is no robust controlled human evidence of rejuvenation, life extension or a general increase in healthspan. The longevity idea remains biologically plausible and worthy of research, but is not confirmed as an effect in humans.
Personal experience
Effects are experienced in everyday life.
Personal reports about Q10 centre on energy, muscle symptoms, exercise tolerance, migraine and preconception use. They show what people observe — and which questions matter to them in practice.
Record the form and meal context
Ubiquinone or ubiquinol, carrier oil, dose and timing relative to meals can change exposure.
Observe the relevant outcome
Perceived energy, migraine days, pain and exercise tolerance are different experiences and should not be merged into one overall effect.
Consider time and accompanying factors
Changes in statins, exercise, sleep, other supplements and natural fluctuations can help shape the experience.
Ubiquinone, ubiquinol & bioavailability
Formulation can matter more than redox state.
Q10 is highly lipophilic and practically insoluble in water. Equal milligrams on the label therefore do not automatically mean equal absorption.
Ubiquinone
The oxidised, more stable form. Crystal size, polymorphism, carrier oil and thermal dispersion influence how well it dissolves and is absorbed.
Ubiquinol
The reduced form, more susceptible to oxidation. Stabilised ubiquinol can achieve high plasma exposure; this does not imply general clinical superiority.
Oils, micelles and liposomes
Oil-based softgels, water-dispersible systems, emulsions, cyclodextrins and liposomes are product-specific technologies. “Liposomal” alone is not a uniform quality characteristic.
How much Q10 appears in the blood?
How much reaches the heart, muscle or other target tissues?
Does the intended biological process change?
Do symptoms, function or clinical events improve?
After oral intake, a large proportion is measured in the blood as ubiquinol — even when ubiquinone was taken. This shows efficient conversion in the body. It does not prove that every formulation is absorbed equally.
Specialist medical contexts
When Q10 is part of a disease.
Defined genetic deficiencies and idiopathic diseases must not be confused. Here, the diagnosis determines the significance of Q10.
Primary CoQ10 deficiencies
Pathogenic variants in Q10-biosynthesis genes can cause ataxia, encephalopathy, myopathy, seizures, kidney disease or multi-organ disease courses. Early high-dose treatment can be important in certain phenotypes. It belongs under specialist medical care.
A plasma level is not a diagnosis
A low blood level may be influenced by lipoproteins, disease, diet or medication. Primary deficiencies are assessed from phenotype, genetics and appropriate specialist diagnostics — not from a wellness test alone.
Parkinson’s disease as an important counterexample
The mitochondrial plausibility was strong. Nevertheless, 1.200 or 2.400 mg ubiquinone daily did not slow clinical progression in a phase-III study involving 600 people. A high dose and high blood levels did not replace evidence of efficacy.
Studied doses
Study ranges are not blanket recommendations.
Dose, duration, formulation and population belong together. This overview describes research contexts, not personal instructions for use.
Pharmacokinetics
Common single doses for formulation comparisons; mainly plasma exposure is measured.
Heart failure
Used in many studies; Q-SYMBIO studied 300 mg ubiquinone daily for two years.
SAMS, migraine, fatigue
Heterogeneous ranges over weeks to months; results cannot be transferred between all formulations.
Fertility
Often for two to six months; surrogate parameters dominate the research.
Parkinson’s study
High-dose range in QE3 — without clinical benefit. No general justification for high doses.
Primary deficiencies
Specialist indication with variable response and specialist medical monitoring.
Safety & interactions
Usually well tolerated — not independent of context.
Q10 was generally well tolerated in many studies. Safety nevertheless depends on dose, duration, diseases, medication and the population group.
The most important interaction
Keep warfarin and INR in view.
Case reports describe a reduced anticoagulant effect, whereas a small randomised crossover trial found no clinically relevant influence. Coordinated INR monitoring is sensible when starting, changing the dose or stopping.
Stomach, bowel and sleep
Nausea, reduced appetite, abdominal discomfort, diarrhoea, headache, skin reactions or sleep disturbances are possible.
Blood pressure and glucose
Additive effects with blood-pressure- or glucose-lowering treatment are possible and should be monitored during such treatment.
Cancer treatment
Because of its antioxidant properties, Q10 should not be used during oncology treatment without consultation. The direction of possible interactions is not established in general.
Special population groups
Robust general safety data are lacking for pregnancy, breastfeeding, children without a defined mitochondrial disease and long-term high-dose use.
Regulatory context
Biological importance is not advertising authorisation.
200 mg in the daily dose
The Swiss food-supplement ordinance lists coenzyme Q10, ubiquinone and ubiquinol with a maximum of 200 mg in the recommended daily dose. The current version must be checked anew for each specific product.
No general authorisation of Q10 claims
For the general Q10 claims assessed, including energy, blood pressure, antioxidant protection, cognition and performance, EFSA did not confirm a sufficient cause-and-effect relationship.
Not “vitamin Q10”
Q10 is produced in the body and has no generally recognised status as an essential vitamin. Coenzyme Q10, ubiquinone-10 and ubiquinol-10 are precise terms.
Frequently asked questions
The key distinctions at a glance.
Many misunderstandings arise when redox form, absorption, tissue levels, biomarkers and clinical benefit are merged into a single statement.
01Is ubiquinol the active and ubiquinone the inactive Q10?
No. Ubiquinol is the reduced and ubiquinone the oxidised form. Both are interconverted in the body and perform different functions as redox partners. Ubiquinol acts particularly as a lipophilic electron donor and radical scavenger; ubiquinone is, among other things, an electron acceptor. “Active versus inactive” describes this system incorrectly.
02Is ubiquinol always better absorbed?
This is not established in general. Small direct comparisons show substantial individual variation and are influenced by carrier oil, crystal structure, dispersion and other formulation characteristics. A well-formulated ubiquinone can achieve higher plasma levels than standard ubiquinone and, in some comparisons, than ubiquinol.
03What does better bioavailability mean?
Usually it means a higher or more sustained concentration in the blood. This is pharmacokinetically relevant, but proves neither a higher concentration in the heart or muscle nor a stronger clinical effect. Plasma exposure, tissue uptake, target effect and health benefit are four different levels of evidence.
04Does Q10 help with statin-related muscle symptoms?
Some studies and experiences support this, while other studies find no reliable average benefit. The overall findings are low-certainty and inconsistent. Statins can lower plasma Q10; this does not automatically imply a muscle deficiency. New or severe muscle symptoms should be medically assessed regardless of Q10 use.
05How positive is the evidence in heart failure?
It is more positive than in most other Q10 applications. Q-SYMBIO and syntheses show clinically relevant signals for mortality and hospital admissions. However, the evidence relies heavily on a few studies and older background therapy. Q10 is not a replacement for modern guideline-based treatment.
06Is Q10 an anti-ageing or longevity agent?
Q10 has a central mitochondrial function and a biologically plausible connection to ageing processes. In humans, however, neither rejuvenation, life extension nor a general increase in healthspan has been demonstrated for Q10 alone.
07Does a low plasma level mean Q10 deficiency?
Not automatically. Plasma Q10 depends strongly on blood lipids and lipoproteins and primarily reflects circulating exposure. Diagnosing a primary genetic deficiency requires specialist assessment of phenotype, genetics and, where appropriate, suitable tissue or biosynthesis investigations.
08Should Q10 be taken with fat?
Q10 is highly fat-soluble. A meal containing fat can support solubilisation, micelle formation and absorption. The magnitude of the effect also depends on the specific formulation. This pharmacokinetic information is not an individual recommendation for use.
Study-specific claims
How likely is each narrowly defined statement to be true?
Each percentage refers exclusively to the claim written beside it. The assessment is not whether a substance “works overall”, but how plausible the specific statement is in light of the study, counterfindings and applicability.
Two different measures: the small bars in the effect cards assess the strength of two evidence bases. The detailed percentages below instead assess the probability of each specifically formulated claim. Study quality is an important basis for this, but is not equivalent to truth.
Crane et al. 1957 / Mitchell 1975approx. 95 %
Coenzyme Q10 is a central electron carrier in the mitochondrial respiratory chain.
Estimated probability that this claim is true: approx. 95 %
Rationale: Fundamental, extensively replicated biochemistry; this alone does not imply a therapeutic effect of additional intake.
Q-SYMBIO 2014approx. 70 %
300 mg Q10 daily in addition to the standard therapy of the time reduce major cardiovascular events over two years in chronic heart failure.
Estimated probability that this claim is true: approx. 70 %
Rationale: Long-term randomised controlled trial with clinical endpoints; the result depends heavily on one study and background therapy that is now partly outdated.
Cochrane review 2021approx. 65 %
Q10 added to treatment reduces mortality and hospital admissions in heart failure.
Estimated probability that this claim is true: approx. 65 %
Rationale: Positive pooled signals, but largely driven by Q-SYMBIO; study numbers, precision and applicability to modern therapy limit certainty.
Heart-failure meta-analysis 2024approx. 65 %
Q10 provides additional clinical benefit in heart failure.
Estimated probability that this claim is true: approx. 65 %
Rationale: More studies and positive signals for events and function, alongside heterogeneity and dependence on a few studies with many events.
Dohlmann et al. 2022approx. 75 %
In statin users with muscle symptoms, Q10 does not correct a demonstrable muscle-Q10 deficiency and does not reliably improve muscle function.
Estimated probability that this claim is true: approx. 75 %
Rationale: Direct muscle measurements and controlled design; limited sample, but important mechanistic counterevidence.
SAMS meta-analysis 2025approx. 50 %
Q10 reduces statin-associated muscle pain by a clinically relevant amount on average.
Estimated probability that this claim is true: approx. 50 %
Rationale: Small pooled effect from seven small RCTs; high heterogeneity and conflicting earlier syntheses prevent a stable judgement.
Migraine meta-analysis 2021approx. 65 %
Q10 slightly reduces the frequency and duration of migraine attacks.
Estimated probability that this claim is true: approx. 65 %
Rationale: Several small controlled studies show a more consistent signal for frequency and duration than for pain severity; precision remains limited.
Fatigue meta-analysis 2022approx. 60 %
Q10 slightly reduces fatigue on average in different studied populations.
Estimated probability that this claim is true: approx. 60 %
Rationale: 13 RCTs with a moderate pooled effect, but heterogeneous causes, doses and measurement instruments.
FMD meta-analysis 2012approx. 65 %
Q10 improves flow-mediated vasodilation in selected at-risk populations.
Estimated probability that this claim is true: approx. 65 %
Rationale: Positive surrogate signal from small studies; no direct conclusion about heart attack, stroke or lifespan.
Cochrane blood-pressure review 2016approx. 35 %
Q10 lowers blood pressure by a clinically relevant amount in primary hypertension.
Estimated probability that this claim is true: approx. 35 %
Rationale: The stricter analysis found no convincing robust effect; small older studies and methodological uncertainty dominate.
Lafuente et al. 2013approx. 65 %
Q10 improves selected semen parameters in men with fertility problems.
Estimated probability that this claim is true: approx. 65 %
Rationale: Several small studies support surrogate improvements; pregnancy and live birth are not reliably demonstrated.
Bentov et al. 2014approx. 30 %
Q10 increases the chance of pregnancy or live birth in older IVF patients.
Estimated probability that this claim is true: approx. 30 %
Rationale: Small, prematurely stopped study without a robust advantage in patient-relevant outcomes.
QE3 Parkinson’s RCT 2014approx. 10 %
1.200 to 2.400 mg Q10 daily slow early Parkinson’s disease.
Estimated probability that this claim is true: approx. 10 %
Rationale: A large phase-III RCT with 600 participants was stopped for lack of efficacy; this is strong direct counterevidence.
KiSel-10 2013approx. 70 %
The combination of selenium and Q10 reduces cardiovascular mortality in older people with low selenium status.
Estimated probability that this claim is true: approx. 70 %
Rationale: Randomised long-term signal with follow-ups; the combination design prevents attribution to Q10 alone.
López-Lluch et al. 2020approx. 90 %
The specific Q10 formulation substantially influences the exposure achieved in the blood.
Estimated probability that this claim is true: approx. 90 %
Rationale: Pharmacokinetic comparisons show large formulation and individual differences; plasma exposure is nevertheless not evidence of clinical benefit.
KiSel-10 2013 — attribution to a single substanceCannot be reliably quantified
The benefit observed in KiSel-10 was caused by Q10 alone.
Estimated probability that this claim is true: cannot be reliably quantified
Rationale: Selenium and Q10 were tested together against placebo. The study design cannot separate the contributions of the two components.
Important: “not independently supported” does not mean “disproved”. Conversely, a lack of disproof is not evidence of efficacy. Substance form, dose, population, duration and endpoint limit every statement.
Sources & transparency
The history of effects and the current research have distinct functions.
This profile combines 24 documented Q10 claims and eight reconstructed shifts in meaning with a separate scientific assessment of 58 sources. The effects cards therefore place sources on origins alongside sources for today’s overall assessment, without confusing them.
Transparency notice
The AFEGA Anti-Aging-Shop, operated separately from the AFEGA Research Group, also sells Q10 products. The scientific assessment is carried out independently of product interests. This profile is not a product appraisal.
- 01Crane et al. 1957: first isolation ↗
- 02Mitchell 1975: Q cycle ↗
- 03CoQ biochemistry and biosynthesis 2023 ↗
- 04Bioavailability — overview 2020 ↗
- 05Formulation comparison 2020 ↗
- 06Q-SYMBIO 2014 ↗
- 07Cochrane: heart failure 2021 ↗
- 08SAMS meta-analysis 2025 ↗
- 09Migraine meta-analysis 2021 ↗
- 10Fatigue meta-analysis 2022 ↗
- 11Male fertility 2013 ↗
- 12Parkinson’s phase III 2014 ↗
- 13Primary CoQ10 deficiency — GeneReviews ↗
- 14Safety assessment 2008 ↗
- 15NCCIH: Coenzyme Q10 ↗
- 16EFSA: assessment of general Q10 claims ↗
- 17Swiss food-supplement ordinance ↗
AFEGA’s perspective
Q10 shows how a fundamental molecule can become a medical idea, a personal experience and a longevity narrative — and why each of these levels deserves its own examination.Go to the substance library →